Why I’ve Bought Reckitt Benckiser Group plc’s Spin-Off, Indivior PLC

Reckitt Benckiser Group Plc’s (LON: RB) spin-off Indivior PLC (LON: INDV) looks to be undervalued.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

At the end of last year, Reckitt Benckiser (LSE: RB) spun off its pharmaceutical division — previously named RB Pharmaceuticals — into a new company called Indivior (LSE: INDV). Reckitt’s management has been trying to refocus the company’s portfolio over the past year or so, and the Indivior spin-off was part of this plan.

Reckitt has been trying to dispose of Indivior for some time. The pharmaceutical company’s sales have been on the slide after US regulators gave the green light to other manufacturers to produce rival generic versions of its heroin substitute drug, Suboxone.

And Indivior’s declining revenues have impacted Reckitt’s growth. For example, during the third quarter Reckitt’s sales only expended by 2%, although growth would have been 3% excluding Indivior. Reckitt is expecting full-year revenue growth of 4% to 5% now Indivior has been spun off. 

An interesting opportunity 

On its first day of trading, Indivior jumped by 17% as demand for the company’s shares was high. It’s easy to see why. Indivior was spun off in a hurry and Reckitt, it seems, couldn’t be bothered to wait around to get the best price.

Indivior is a global leader in the treatment of opioid dependence, with over two decades of history behind it. The group’s core products, namely the drug Suboxone, are sold in up to 44 countries.

Sales of Suboxone tablets have recently come under attack from generic competitors. However, Indivior has fought back with Suboxone film, the sales of which are holding up relatively well. 

Still, there’s no denying the fact that Indivior is under pressure. Total revenues from the Indivior business are expected to fall by more than 12% this year and profits are likely to fall by 25%, due to lower net revenues but also higher R&D costs.

But here’s the thing, at present levels, Indivior is cheap, really cheap. The company currently trades at an estimated 2014 P/E of 5 and a forward P/E of 9, both of which are significantly below the pharmaceutical sector average P/E of 30. Full-year 2014 earnings per share are expected to be somewhere in the region of 31p per share.

Management has stated that it will payout 40% of earnings as a dividend. So, based on this, at current levels Indivior is set to support a yield of around 7% this year.  

Additionally, the company is highly cash-generative and a gross margin of nearly 80% has been reported for the past five years. 

Room for growth 

Indivior is cheap but the company is cheap for a reason; sales are falling. However, now the company is independent it can focus on growth, and Indivior’s potential market is huge. 

Twelve million people abuse opioids annually in the US and 2.5m of them need treatment for addiction. At present Indivior only treats a quarter of these patients.

What’s more, the company has a pipeline of drugs under development that will hit the market over the next few years. These new treatments include drugs for cocaine overdose and alcohol dependency, as well as treatments for schizophrenia. One new product launch is planned every year from 2016 through to 2020. With over 250 sales reps in the US alone, Indivior already has the infrastructure in place to shift these new products. 

Cheap growth 

So all in all, Indivior is cheap, cash-generative, is set to support a hefty dividend yield and has the foundations in place to grow rapidly from 2016 onwards. I believe the company offers long-term growth and income at an extremely attractive price. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of Indivior. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Businessman hand flipping wooden block cube from 2024 to 2025 on coins
Investing Articles

2 soaring dividend shares to consider for both growth and income!

This Fool's spotted a rare occurrence: two dividend shares delivering impressive growth while maintaining attractive yields.

Read more »

Two business people sitting at cafe working on new project using laptop. Young businesswoman taking notes and businessman working on laptop computer.
Investing Articles

After crashing 40% in a year, is this a bargain basement value stock?

This once-beloved growth stock has fallen from grace as its sales momentum stalls, but after multiple price crashes, is it…

Read more »

Shot of an young mixed-race woman using her cellphone while out cycling through the city
Investing Articles

Simple truths about starting an ISA

Dr James Fox explains how investors can open a Stocks and Shares ISA and aim for long-term wealth generation. Getting…

Read more »

A senior man and his wife holding hands walking up a hill on a footpath looking away from the camera at the view. The fishing village of Polperro is behind them.
Investing Articles

Here’s how I’m using my ISAs to target retirement riches

A comfortable retirement's on my mind and I'm using my ISAs to help me get there. But while my cash…

Read more »

Businessman with tablet, waiting at the train station platform
Investing Articles

134,000 reasons why I prefer FTSE 100 stocks over cash savings!

The results are in! Investing in FTSE 100 stocks can be a superior way to build wealth than saving, as…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

Here’s how long it’s taken £1k of Nvidia stock to turn into £10k today!

Our writer explains how money invested in Nvidia stock less than three years ago has grown in value over tenfold…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
US Stock

3 red flags I’m seeing right now for the S&P 500

Jon Smith points out some concerns he has with the S&P 500 at current levels and picks one stock he's…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

UK dividend shares are outperforming US tech stocks!

UK dividend shares aren’t just for passive income investors. Over the last 12 months, they’ve been outperforming their US tech…

Read more »